These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35140266)

  • 21. Genistein Activates Transcription Factor EB and Corrects Niemann-Pick C Phenotype.
    Argüello G; Balboa E; Tapia PJ; Castro J; Yañez MJ; Mattar P; Pulgar R; Zanlungo S
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retinal axonal degeneration in Niemann-Pick type C disease.
    Havla J; Moser M; Sztatecsny C; Lotz-Havla AS; Maier EM; Hizli B; Schinner R; Kümpfel T; Strupp M; Bremova-Ertl T; Schneider SA
    J Neurol; 2020 Jul; 267(7):2070-2082. PubMed ID: 32222928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitors correct the cholesterol storage defect in most Niemann-Pick C1 mutant cells.
    Pipalia NH; Subramanian K; Mao S; Ralph H; Hutt DM; Scott SM; Balch WE; Maxfield FR
    J Lipid Res; 2017 Apr; 58(4):695-708. PubMed ID: 28193631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single Cell Transcriptome Analysis of Niemann-Pick Disease, Type C1 Cerebella.
    Cougnoux A; Yerger JC; Fellmeth M; Serra-Vinardell J; Martin K; Navid F; Iben J; Wassif CA; Cawley NX; Porter FD
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32731618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. δ-Tocopherol reduces lipid accumulation in Niemann-Pick type C1 and Wolman cholesterol storage disorders.
    Xu M; Liu K; Swaroop M; Porter FD; Sidhu R; Firnkes S; Ory DS; Marugan JJ; Xiao J; Southall N; Pavan WJ; Davidson C; Walkley SU; Remaley AT; Baxa U; Sun W; McKew JC; Austin CP; Zheng W
    J Biol Chem; 2012 Nov; 287(47):39349-60. PubMed ID: 23035117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of N-acetylcysteine in phenotypic suppression of mouse models of Niemann-Pick disease, type C1.
    Fu R; Wassif CA; Yanjanin NM; Watkins-Chow DE; Baxter LL; Incao A; Liscum L; Sidhu R; Firnkes S; Graham M; Ory DS; Porter FD; Pavan WJ
    Hum Mol Genet; 2013 Sep; 22(17):3508-23. PubMed ID: 23666527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Niemann-Pick C1 mouse models, glial-only expression of the normal gene extends survival much further than do changes in genetic background or treatment with hydroxypropyl-beta-cyclodextrin.
    Marshall CA; Watkins-Chow DE; Palladino G; Deutsch G; Chandran K; Pavan WJ; Erickson RP
    Gene; 2018 Feb; 643():117-123. PubMed ID: 29223359
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Niemann-Pick Disease Type C: Induced Pluripotent Stem Cell-Derived Neuronal Cells for Modeling Neural Disease and Evaluating Drug Efficacy.
    Yu D; Swaroop M; Wang M; Baxa U; Yang R; Yan Y; Coksaygan T; DeTolla L; Marugan JJ; Austin CP; McKew JC; Gong DW; Zheng W
    J Biomol Screen; 2014 Sep; 19(8):1164-73. PubMed ID: 24907126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Finding pathogenic commonalities between Niemann-Pick type C and other lysosomal storage disorders: Opportunities for shared therapeutic interventions.
    Yañez MJ; Marín T; Balboa E; Klein AD; Alvarez AR; Zanlungo S
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165875. PubMed ID: 32522631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Altered distribution and function of natural killer cells in murine and human Niemann-Pick disease type C1.
    Speak AO; Te Vruchte D; Davis LC; Morgan AJ; Smith DA; Yanjanin NM; Simmons L; Hartung R; Runz H; Mengel E; Beck M; Imrie J; Jacklin E; Wraith JE; Hendriksz C; Lachmann R; Cognet C; Sidhu R; Fujiwara H; Ory DS; Galione A; Porter FD; Vivier E; Platt FM
    Blood; 2014 Jan; 123(1):51-60. PubMed ID: 24235134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-mRNA splicing defects and RNA binding protein involvement in Niemann Pick type C disease.
    Paron F; Dardis A; Buratti E
    J Biotechnol; 2020 Jul; 318():20-30. PubMed ID: 32387451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential Effects of 2-Hydroxypropyl-Cyclodextrins on Lipid Accumulation in
    Hoque S; Kondo Y; Sakata N; Yamada Y; Fukaura M; Higashi T; Motoyama K; Arima H; Higaki K; Hayashi A; Komiya T; Ishitsuka Y; Irie T
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32019132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanded access with intravenous hydroxypropyl-β-cyclodextrin to treat children and young adults with Niemann-Pick disease type C1: a case report analysis.
    Hastings C; Vieira C; Liu B; Bascon C; Gao C; Wang RY; Casey A; Hrynkow S
    Orphanet J Rare Dis; 2019 Oct; 14(1):228. PubMed ID: 31639011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-content screen for modifiers of Niemann-Pick type C disease in patient cells.
    Pugach EK; Feltes M; Kaufman RJ; Ory DS; Bang AG
    Hum Mol Genet; 2018 Jun; 27(12):2101-2112. PubMed ID: 29659804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C.
    Héron B; Valayannopoulos V; Baruteau J; Chabrol B; Ogier H; Latour P; Dobbelaere D; Eyer D; Labarthe F; Maurey H; Cuisset JM; de Villemeur TB; Sedel F; Vanier MT
    Orphanet J Rare Dis; 2012 Jun; 7():36. PubMed ID: 22676771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated cerebrospinal fluid ubiquitin C-terminal hydrolase-L1 levels correlate with phenotypic severity and therapeutic response in Niemann-Pick disease, type C1.
    Cawley NX; Giddens S; Farhat NM; Luke RA; Scott KEJ; Mohamed HO; Dang Do A; Berry-Kravis E; Cologna SM; Liu F; Porter FD
    Mol Genet Metab; 2023 Nov; 140(3):107656. PubMed ID: 37517328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro evaluation of 2-hydroxyalkylated β-cyclodextrins as potential therapeutic agents for Niemann-Pick Type C disease.
    Kondo Y; Tokumaru H; Ishitsuka Y; Matsumoto T; Taguchi M; Motoyama K; Higashi T; Arima H; Matsuo M; Higaki K; Ohno K; Irie T
    Mol Genet Metab; 2016 Jul; 118(3):214-219. PubMed ID: 27184436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of a glycinated bile acid biomarker for diagnosis and assessment of response to treatment in Niemann-pick disease type C1.
    Sidhu R; Kell P; Dietzen DJ; Farhat NY; Do AND; Porter FD; Berry-Kravis E; Reunert J; Marquardt T; Giugliani R; Lourenço CM; Wang RY; Movsesyan N; Plummer E; Schaffer JE; Ory DS; Jiang X
    Mol Genet Metab; 2020 Dec; 131(4):405-417. PubMed ID: 33257258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclodextrins applied to the treatment of lysosomal storage disorders.
    Ishitsuka Y; Irie T; Matsuo M
    Adv Drug Deliv Rev; 2022 Dec; 191():114617. PubMed ID: 36356931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mitochondrial GSH replenishment as a potential therapeutic approach for Niemann Pick type C disease.
    Torres S; Matías N; Baulies A; Nuñez S; Alarcon-Vila C; Martinez L; Nuño N; Fernandez A; Caballeria J; Levade T; Gonzalez-Franquesa A; Garcia-Rovés P; Balboa E; Zanlungo S; Fabrías G; Casas J; Enrich C; Garcia-Ruiz C; Fernández-Checa JC
    Redox Biol; 2017 Apr; 11():60-72. PubMed ID: 27888692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.